Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus

Transplant International

Volumn 25, Issue 1, 2012, Pages 48-55

  Lauzurica, Ricardo ^a   Morales, José M ^b   Van Hooff, Johannes ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

calcineurin inhibitor; immunosuppressant; kidney transplantation; tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NUTRITIONAL DISORDER; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STEADY STATE; VASCULAR DISEASE;

ADULT; BIOPSY; DELAYED-ACTION PREPARATIONS; EUROPE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME;

EID: 83955161702     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01366.x     Document Type: Article

References (20)

1. Morrissey PE, Flynn ML, Lin S,. Medication noncompliance and its implications in transplant recipients. Drugs 2007; 67: 1463.
2. Weng FL, Israni AK, Joffe MM, et al., Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839.
3. Ichimaru N, Kakuta Y, Abe T, et al., Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants. Transplant Proc 2008; 40: 1362.
4. Kramer BK, Charpentier B, Backman L, et al., Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632.
5. Silva HT Jr, Yang HC, Abouljoud M, et al., One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
6. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al., Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505.
7. van Hooff JP, van der Walt I, Kallmeyer J, et al., Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. Presented at the 3rd International Congress of Immunosuppression. San Diego, CA, 8-11 December (abstract 26).
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
9. Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
10. Alloway R, Steinberg S, Khalil K, et al., Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867.
11. van Hooff JP, Alloway RR, Trunečka P, Mourad M,. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant 2011; 25: E1-12.
12. Alloway R, Steinberg S, Khalil K, et al., Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648.
13. Florman S, Alloway R, Kalayoglu M, et al., Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639.
14. Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, et al., Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplant Proc 2009; 41: 2326.
15. Alloway R, Steinberg S, Khalil K, et al., Conversion of stable kidney disease transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867.
16. Guirado L, Cantarell C, Franco A, et al., Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011; 11: 1965.
17. o concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523.
18. Scott LJ, McKeage K, Keam SJ, Plosker GL,. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
19. Gaston RS, Hudson SL, Ward M, Jones P, Macon R,. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 1999; 31: 21S.
20. Denhaerynck K, Dobbels F, Cleemput I, et al., Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int 2005; 18: 1121.